

This is an Open Access document downloaded from ORCA, Cardiff University's institutional repository: <https://orca.cardiff.ac.uk/id/eprint/129660/>

This is the author's version of a work that was submitted to / accepted for publication.

Citation for final published version:

Soda, Takahiro, McLoughlin, Declan M., Clark, Scott R., Oltedal, Leif, Kessler, Ute, Haavik, Jan, Bousman, Chad, Smith, Daniel J., Bioque, Miquel, Clements, Caitlin C., Loo, Colleen, Vila-Rodriguez, Fidel, Minelli, Alessandra, Mickey, Brian J., Milev, Roumen, Docherty, Anna R., Langan Martin, Julie, Achtyes, Eric D., Arolt, Volker, Redlich, Ronny, Dannlowski, Udo, Cardoner, Narcis, Clare, Emily, Craddock, Nick, Di Florio, Arianna, Dmitrzak-Weglarz, Monika, Forty, Liz, Gordon-Smith, Katherine, Husain, Mustafa, Ingram, Wendy M., Jones, Lisa, Jones, Ian, Juruena, Mario, Kirov, George, Landén, Mikael, Müller, Daniel J., Nordensköld, Axel, Pålsson, Erik, Paul, Meethu, Permoda, Agnieszka, Pliszka, Bartłomiej, Rea, Jamie, Schubert, Klaus O., Sonnen, Joshua A., Soria, Virginia, Stageman, Will, Takamiya, Akihiro, Urretavizcaya, Mikel, Watson, Stuart, Zavorotny, Maxim, Young, Allan H., Vieta, Eduard, Rybakowski, Janusz K., Gennarelli, Massimo, Zandi, Peter P., Sullivan, Patrick F. and Baune, Bernhard T. 2020. International consortium on the genetics of electroconvulsive therapy and severe depressive disorders (Gen-ECT-ic). *European Archives of Psychiatry and Clinical Neuroscience* 270, pp. 921-932. 10.1007/s00406-019-01087-w

Publishers page: <http://dx.doi.org/10.1007/s00406-019-01087-w>

Please note:

Changes made as a result of publishing processes such as copy-editing, formatting and page numbers may not be reflected in this version. For the definitive version of this publication, please refer to the published source. You are advised to consult the publisher's version if you wish to cite this paper.

This version is being made available in accordance with publisher policies. See <http://orca.cf.ac.uk/policies.html> for usage policies. Copyright and moral rights for publications made available in ORCA are retained by the copyright holders.



International Consortium on the Genetics of Electroconvulsive Therapy and Severe Depressive Disorders (Gen-ECT-ic)

Takahiro Soda¹ · Declan M. McLoughlin² · Scott R. Clark³ · Leif Olteidal^{4,28} · Ute Kessler^{4,5} · Jan Haavik^{5,6} · Chad Bousman⁷ · Daniel J. Smith⁸ · Miquel Bioque⁹ · Caitlin C. Clements¹⁰ · Colleen Loo^{11,12} · Fidel Vila-Rodriguez¹³ · Alessandra Minelli¹⁴ · Brian J. Mickey¹⁵ · Roumen Milev^{16,17} · Anna R. Docherty¹⁵ · Julie Langan Martin⁸ · Eric D. Achtyes¹⁸ · Volker Arolt¹⁹ · Ronny Redlich¹⁹ · Udo Dannlowski¹⁹ · Narcis Cardoner²⁰ · Emily Clare²¹ · Nick Craddock²² · Arianna Di Florio²² · Monika Dmitrzak-Weglarz²³ · Liz Forty²² · Katherine Gordon-Smith²⁴ · Mustafa Husain²⁵ · Wendy M. Ingram²⁶ · Lisa Jones²⁴ · Ian Jones²² · Mario Juruena²⁷ · George Kirov²² · Mikael Landén²⁹ · Daniel J. Müller³⁰ · Axel Nordensköld³¹ · Erik Pålsson²⁹ · Meethu Paul²¹ · Agnieszka Permoda³³ · Bartłomiej Pliszka²⁷ · Jamie Rea²¹ · Klaus O. Schubert^{3,32} · Joshua A. Sonnen³³ · Virginia Soria³⁴ · Will Stageman^{21,35} · Akihiro Takamiya³⁶ · Mikel Urretavizcaya³⁴ · Stuart Watson^{21,35} · Maxim Zavorotny³⁷ · Allan H. Young²⁷ · Eduard Vieta⁹ · Janusz K. Rybakowski^{33,38} · Massimo Gennarelli^{14,39} · Peter P. Zandi⁴⁰ · Patrick F. Sullivan^{1,41,42} · Bernhard T. Baune^{19,43,44}

Abstract

Recent genome-wide association studies have demonstrated that the genetic burden associated with depression correlates with depression severity. Therefore, conducting genetic studies of patients at the most severe end of the depressive disorder spectrum, those with treatment-resistant depression and who are prescribed electroconvulsive therapy (ECT), could lead to a better understanding of the genetic underpinnings of depression. Despite ECT being one of the most effective forms of treatment for severe depressive disorders, it is usually placed at the end of treatment algorithms of current guidelines. This is perhaps because ECT has controlled risk and logistical demands including use of general anaesthesia and muscle relaxants and side-effects such as short-term memory impairment. Better understanding of the genetics and biology of ECT response and of cognitive side-effects could lead to more personalized treatment decisions. To enhance the understanding of the genomics of severe depression and ECT response, researchers and ECT providers from around the world and from various depression or ECT networks, but not limited to, such as the Psychiatric Genomics Consortium, the Clinical Alliance and Research in ECT, and the National Network of Depression Centers have formed the Genetics of ECT International Consortium (Gen-ECT-ic). Gen-ECT-ic will organize the largest clinical and genetic collection to date to study the genomics of severe depressive disorders and response to ECT, aiming for 30,000 patients worldwide using a GWAS approach. At this stage it will be the largest genomic study on treatment response in depression. Retrospective data abstraction and prospective data collection will be facilitated by a uniform data collection approach that is flexible and will incorporate data from many clinical practices. Gen-ECT-ic invites all ECT providers and researchers to join its efforts.

Keywords Electroconvulsive therapy · GWAS · ECT · Severe depression · Major depressive disorder · Bipolar disorder · Genomic · Cognition

Background

Major Depressive Disorder (MDD) is now recognized by the World Health Organisation (WHO) as the single leading cause of disability worldwide. It is a serious and common mood disorder with an estimated international prevalence of 4.4% [52], accounting by itself for over 40% of the functional

impairment attributed to mental health disorders [71]. MDD is the most common mental disorder associated with suicide, and the second leading cause of death in 15–29 year old people [61]. Compared to mild depressive disorder, people with severe episodes have double the odds of death from suicide [29]. The heritability of MDD is estimated to range between 40 and 70% [37], lower than for bipolar disorder (BD).

BD is identified as the sixth leading cause of disability worldwide among all diseases as estimated by the World Health Organisation (WHO) [65]. It affects approximately 2% of the population, and has a suicide rate of 20%, which is even higher than in MDD. Heritability estimates for BD typically fall in the range 60–85% [14] and genetic studies indicate that the disorder follows a polygenic mode of transmission.

The Psychiatric Genomic Consortium (PGC) was established circa 2007 (<https://www.med.unc.edu/pgc/>), with a goal to build large population samples of genomic and phenotypic data suitable for genome-wide exploration of the determinants of diagnosis and outcome in mental illness [62]. It has grown to a collaboration of over 800 investigators from over 38 countries, with more than 900,000 samples from individuals in analysis and is the largest consortium and biological experiment in the history of psychiatry [63]. The Major Depressive Disorder working group (PGC-MDD-WG) and the Bipolar Disorder Working Groups were among the first five collaborations to develop. The PGC recently identified 102 genome-wide significant common variant associations for MDD ($P = 8 \times 10^{-10}$) [31, 72] as well as 30 genome-wide significant common variant associations for bipolar disorder (BD) [60]. The subjects in these studies were heterogeneous and some were poorly characterized. This limits the interpretability and clinical utility of these findings for clinicians. Based on more recent observations that the severity of MDD is correlated with MDD polygenic risk [72] and BD polygenic risk predicts earlier onset of depression [46], these findings suggest a clear and compelling rationale to study the genomics of patients with the most severe forms of mood disorders. The yield of genetic discovery from studying these subjects is expected to be greater than for studies of less severe forms of depressive disorders.

The phenotypic characterization of patients with mood disorders in the numbers required for genome-wide association studies (GWAS, tens of thousands to millions) is challenging. Earlier genetic studies of mood disorders relied on more comprehensive research assessments to characterize the phenotype in detail. Due to demand for greater statistical power, there is now a need to rapidly identify, consent, briefly phenotype, biosample, and genotype people with mood disorders to translate genetic findings into clinical and therapeutically actionable findings.

For practical, conceptual, and procedural reasons, recruiting individuals receiving electroconvulsive therapy (ECT)

is an obvious choice for identifying those with severe depression and with rich clinical information, often in routine clinical settings. First, ECT is administered to those with the most severe forms of mood disorders [2, 30, 33, 57, 70]. Second, patients considered for ECT have undergone detailed psychiatric and medical evaluation to determine their suitability for ECT. Third, patients' mood and treatment response are assessed periodically over the ECT treatment course, which allows analysis of response to ECT. Such a highly standardized protocol provides a rich clinical characterization that is linked to treatment outcomes. Hence, forming an international consortium to rapidly identify, consent, phenotype, biosample, and genotype people who have a history of receiving ECT with available medical records makes use of a relatively highly standardized procedure around the world. People undergoing ECT will also be approached for consent to provide a blood sample, as well as authorize us to collect pertinent history from their medical records. We have created a data collection protocol that allows us to rapidly extract relevant clinical information (20–30 min), including the patient's psychiatric history, medical history, and response to ECT from available medical records.

The ultimate goal of this study is to contribute to predictive algorithms for treatment response in depression. Approximately 80% of patients respond to ECT, according to a large Swedish study, and a significant proportion of patients discontinue or never initiate ECT due to concern about side-effects [11, 49]. To date, research has met limited success in using clinical features to predict response to ECT or likelihood of experiencing side-effects. A recent meta-analysis identified modest predictive power for several clinical features including psychosis as well as older age and, to a lesser extent, depression severity as predictors of response and/or remission to ECT, while it was not possible to be conclusive about melancholia [69]. There is thus a clinical need to develop better methods to predict response and aid patient selection for specific treatments. In other words, we want to learn whether we can, very early on in treatment or even at first presentation, identify people who will likely respond well to ECT versus people who will likely respond poorly or have adverse effects from ECT, to personalize the recommendations for treatment with ECT for those with depression, at an earlier phase of illness than occurs in current clinical practice. This would also allow ECT to be avoided in those patients for whom the physical or cognitive side-effects of ECT would outweigh the benefits of treatment.

ECT: clinical indications, practice, and mechanism of action

Why are patients receiving ECT?

ECT is one of the most rapid and effective treatments for affective symptoms in both MDD and BD [16, 25, 34, 54].

ECT applies an electrical stimulus to induce a brief generalized seizure under controlled conditions. The procedure is performed under general anaesthesia with the use of a muscle relaxant [19]. ECT is a medically safe procedure with a very low mortality of 2.1 per 100,000 treatments [67]. Because of its good evidence base, international guidelines support the use of ECT in cases where depression or mania is resistant to medication and psychotherapy (“treatment resistant”) or where rapid response is desirable such as high suicidality, catatonia, and rapidly deteriorating physical status due to self-neglect [2, 3, 43, 48, 53, 56, 70]. ECT has also been shown to be cost-effective and improve quality of life [23, 58]. It is associated with cognitive side-effects [7] and severe memory-related side-effects in a minority of patients, as well as physiological changes such as hypertension and raised intra-cranial pressure and so requires careful screening and monitoring processes [59, 64, 68]. For these reasons, ECT is usually restricted to the most severe or resistant cases of depression and patients who receive it are well characterized by detailed clinical screening and monitoring practice.

A course of ECT generally requires 6–12 treatments delivered two-to-three times per week. Longitudinal progress, response, and side-effect data are often routinely collected, albeit using different formats and standardized scales, to support treatment decision-making and contribute to the patient’s medical record. Furthermore, blood samples can be easily taken following vascular access for anaesthesia. For these reasons, it is possible to study response to ECT in clinical settings with minimal or no additional procedures. To facilitate collaboration between clinicians of varying experience across international boundaries, the Gen-ECT-ic protocol has been specifically designed to allow flexibility in the quantity and complexity of data and type of outcome scales used. We hope that this study will contribute to improving clinical delivery of ECT by encouraging the systematic collection of ECT response and side-effect data. To that end, we have also partnered with the Clinical Alliance and Research in ECT (CARE) Network [41] and the National Network of Depression Centers [24].

Recent research suggests that ECT may mediate its effects via neuroplastic mechanisms within the brain [9] and it has been shown to increase brain region volumes within the hippocampus [22], although hippocampal enlargement might not explain clinical efficacy of ECT [51]. Though altering electrical stimulus dose, stimulus pulse-width and electrode placement can minimize cognitive side-effects [34, 66], it is not yet fully possible to personalize treatment for an individual patient using clinical, biological, and/or procedural variables alone [21, 38, 56]. Latent class analysis suggests up to five trajectories of response including 13% with no improvement and 31%

with slow improvement [12]. Despite these response trajectories, treatment recommendations are solely based on clinical assessments and broad clinical guidelines with a high variation in treatment frequency, anaesthetic procedures, electrode placements, and stimulation paradigms internationally [36, 41].

Hence, it has been suggested that multimodal prediction approaches that combine clinical, procedural, and biological as well as emerging genomic markers may improve the accuracy of treatment predictions [69]. In the absence of any previous GWAS for ECT response, only candidate gene studies have been conducted, mostly with small underpowered sample sizes, with mixed associations between response and catechol-O-methyltransferase (COMT), dopamine receptor (D2, D3), serotonin-related (tryptophan hydroxylase, 5-HTTLPR transporter, 2A receptor), brain-derived neurotrophic factor (BDNF), and apolipoprotein E (APOE) genotype [4, 10, 15, 17, 40, 56]. The emerging area of multimodal prediction of treatment response to ECT and the absence of reliable candidate or genomic markers of response stimulates a genomic approach to predicting treatment response to ECT in depression. The formation of the Genomics of ECT international consortium (Gen-ECT-ic) in depression aims to build the platform to meet the gap in ECT research and clinical prediction.

Gen-ECT-ic’s scientific goals and objectives

The consortium has been formed to achieve a total sample size of > 30,000 cases over the coming 4–5 years with the following objectives:

The goals and objectives of Gen-ECT-ic are to

1. investigate the genomic underpinnings of severe, treatment-resistant depression;
2. study the genetic contribution of treatment response to ECT;
3. identify genetic markers of patients with increased risk of developing severe cognitive deficits;
4. form the largest clinical study of ECT to date.

The consortium’s ambition is to facilitate clinical research in the field of ECT and more broadly in severe depressive disorders by becoming a repository of clinical and genetic data of subjects with a history of ECT or severe depression. Accordingly, we will ask for permission to recontact participants for future studies. To achieve the above objectives, statistical analyses will be performed using the high-quality and well-established bioinformatics pipeline and expertise of the PGC.

Membership in Gen-ECT-ic

We welcome any ECT provider or researchers who wish to study participants with severe depression that have undergone or may undergo ECT to join Gen-ECT-ic. We also welcome providers and research groups with access to patients/subjects/samples derived from persons with a history of clinically documented severe depression. This includes custodians of biobanks with access to DNA samples or samples from which DNA can be derived. Eligibility of the samples for inclusion into the study will be individually verified using the data collection questionnaire, which is described below. We ask that those who join Gen-ECT-ic agree to the PGC's memorandum of understanding (<https://www.med.unc.edu/pgc/shared-methods/documents-for-data-access/>).

To ensure a constant exchange of ideas between members and allow for rapid realization of Gen-ECT-ic's goals, a monthly conference call is conducted and a listserv has been created which allows for the rapid dissemination of ideas, best practices, as well as a discussion of new developments in ECT and severe depression genomics.

Data and sample collection

The plan for clinical data and DNA sample collection is designed to be as flexible as possible to fit within different clinical workflows of participating ECT centers to capitalize on routine clinical care and minimize the burden of the study on both the patients and provider teams participating in the consortium. Each ECT center will be able to adapt data collection procedures to use the approaches that work best for its clinical operation.

A flexible, modular questionnaire has been developed with this goal in mind. Construction of this questionnaire followed a consensus-based approach with the input of experts in the field of psychiatric genetics, mood disorders, and ECT research, including Members of the NIMH Division of Translational Research, International Society for ECT and Neurostimulation (ISEN), the European Forum for ECT (EFFECT) [8], the Psychiatric Genomics Consortium (PGC) [62], CARE Network [41], NNDC [24] the Consortium for Research in ECT (CORE) [55], the Prolonging Remission in Depressed Elderly (PRIDE) study group [32], and the Global ECT-MRI Research Collaboration (GEM-RIC) [50]. This modular approach achieves the balance of maximizing sample collection as well as clinical characterization of each sample included.

The questionnaire can be used for retrospective (from either clinical records or registry-based information) or prospective data collection, and was designed to streamline data collection on the front end to facilitate later data harmonization. It was designed to capture routinely collected clinical data in a flexible way that would minimize exclusion of

participants from the study. We have arranged the information into three tiers (basic, minimal, and extended), reflecting the variable level of detail in the existing biobanks and repositories and providing flexibility in the commitment of collaborators collecting new data. The data capture form was designed to extract retrospectively or prospectively collected data present within a medical record for referral to an ECT clinic, routine ECT monitoring, or evaluation of severe/treatment-resistant depression. The entire data collection process can be completed in less than 30 min, with access to the existing notes without a specific participant interview. Collaborators have different options to capture varying depth of available clinical data as detailed below. Both paper-based and online versions have been implemented. The online version utilizes REDCap (<https://www.project-redcap.org>) [28], a secure web database application for data collection. Access to collaborators can be forwarded via a simple email with hyperlink. The data abstraction form in its paper format is attached as supplement.

Using the three tiers of data, collaborators have different options to capture varying depth of available clinical data.

Tier 1: basic data

Providing samples with basic data (lowest tier) is sufficient for membership in the consortium (sections 1–4). This includes demography, primary and secondary clinical diagnoses, indication for ECT, confirmation that the subject meets study inclusion criteria, and verification of consent. In particular, the diagnosis includes important clinical qualifiers like severity, psychotic features, and treatment resistance.

These data should be available even for samples obtained from pre-existing registries and biobanks with little accompanying clinical information, and it takes less than 5 min to complete.

Tier 2: minimal clinical data

Tier 2 (sections 5–7) captures information on the clinical response to ECT for a selected index acute treatment series. This includes information on the primary indication for ECT and initial ECT administration parameters for the series (section 5). It also includes information on clinical assessments that are routinely captured to document efficacy and safety during the ECT series. The primary efficacy assessment is the Clinical Global Impression-Severity and/or Improvement scales (CGI-S and CGI-I) for before and after the ECT series. The CGI-S and CGI-I scales have been shown to be valid and reliable measures of clinical response that are sensitive to change [5, 26, 44], and have been widely used in numerous clinical trials in psychiatry. In the interest of maximizing flexibility, other efficacy assessments can be provided if the CGI is not available. These include commonly

used measures of depressive symptoms, such as the Montgomery-Åsberg Depression Rating Scale (MADRS) [45], the Hamilton Depression Rating Scale (HAM-D) [27], the Patient Health Questionnaire-9 (PHQ-9) [18, 35, 39], or equivalent. Mania measurements include Young's Mania Rating Scale [73]. For safety assessments, the instrument will capture information on the most commonly used measures of cognitive function in ECT, including the THINC-it tool [42], the Mini-Mental Status Examination (MMSE) [20], the Montreal Cognitive Assessment (MOCA) [47], and any measure of autobiographical memory.

Tier 3: extended clinical data

Tier 3 (sections 8–16) captures a richer set of clinical information that is routinely, but not always, collected during ECT. This includes the following information: extended psychiatric history and psychiatric comorbidities; history of mania; details of past pharmacological treatment trials, psychotherapy and stimulation therapies; medical comorbidities; history of substance use disorders; family history; and history of prior ECT.

Standard operation procedures

Standard operating procedures (SOPs) are provided for the collection of clinical data and the collection and processing of biosamples. The minimal sample requirement is DNA or saliva or peripheral whole blood for DNA extraction. Whole blood can also be processed to extract RNA and serum and plasma for proteomic and other analyses.

Local sites will be responsible for the consent of individual participants, storage of consent forms, as well as storage of linker information to the deidentified data related to this project. Each site will be responsible for applying and obtaining the appropriate ethical permissions required at their site that adheres to the local site's ethics committee, state/province/district, and countries laws and regulations. Each site that consents the participants will also be responsible for the deletion of identifiable data at their local sites should participants decide to withdraw their consent to participate. For data that have already been transmitted to the PGC in deidentified form, the site will then be responsible for informing the data committee the deidentified code number associated with the participant that has withdrawn consent, so that their data may be deleted. Reasonable measures will be taken to delete their data. However, summary statistics obtained from analysis with this individual's data, as well as any published results would likely not be able to be withdrawn.

Non-personal data, that is, deidentified clinical data and deidentified genetic data linked by code will be stored and analyzed in a manner consistent with the practices of

the PGC. The PGC has vast experience in these matters. In brief, PGC data are stored in the Dutch LISA/Genetic Cluster Computer hosted by Surfsara (<https://surfsara.nl/systems/lisa>) with ISO 27001 certification. Data obtained via PGC are not allowed to be removed from the LISA cluster. Any individual who requests access to the PGC data is required to sign the PGC Memorandum of Understanding (MOU), become approved to become a member of the PGC and submit a proposal to the PGC-MDD workgroup. This workgroup will review the qualifications of the individual PGC member as well as the scientific merit of the project to determine whether this request would be approved. After approval by the workgroup chair, the individual will then apply for data access via the secure PGC data access web portal. The MDD workgroup representative will oversee the approval and access process. The data access committee keeps record of all permissions and approvals and the PGC has the capacity to monitor all data accessed. Data at the individual level require further agreements and documentation. More information can be found <https://www.med.unc.edu/pgc/shared-methods/>.

Site description

Current consortium members consist of investigators and clinicians from high-volume ECT centers, investigators with access to biorepositories linked to medical records, and researchers in the field of ECT. Table 1 summarizes these sites at the time of submission.

Gen-ECT-ic's current project and long-term mission

Gen-ECT-ic is poised to assess the “pharmacogenomics” of ECT treatment in mood disorders, including both treatment response and emergence of adverse effects. The combined GenECT-ic sample (current sample size of $N = 11,400$) is the largest sample set to date to investigate response to ECT on a genome-wide scale and, in addition, we aim to create the largest collection of clinical data on ECT response. As a first project, Gen-ECT-ic intends to conduct a GWAS of response to ECT as compared to non-response to ECT in ECT recipients with a severe depressive episode, regardless of whether the depressive episode is in the context of MDD or Bipolar disorder. As a second major project, Gen-ECT-ic intends to conduct a GWAS of inpatients with severe depression (TDR) (MDD or BD) as compared to mild-to-moderate depression. This comparator group will include participants recruited retrospectively from studies contributing to the PGC with mild-to-moderate MDD (MADRS < 24 or HAMD < 18) and mild-to-moderate BD (MADRS < 24 or HAMD < 18 ; YMRS < 20) who have not undergone ECT.

Table 1 Overview of sites providing samples in the Gen-ECT-ic Consortium

Institution/network	Country	Existing cases	ECT per year	Biosampling complete
GEMRIC	Multinational	300	–	–
Australia ECT Network CARE	Australia	–	500	–
University of New South Wales	Australia	–	500	–
Northside Group Saint Leonard's Clinic	Australia	–	80	–
Providence Care Hospital, Queen's University	Canada	50	100	–
Sunnybrook Health Sciences Centre	Canada	50	100	–
University of Calgary	Canada	–	50	–
University of British Columbia	Canada	50	30	–
Central Institute Mannheim	Germany	–	100	100
University of Bielefeld	Germany	–	100	–
University of Marburg	Germany	–	100	100
University of Munster	Germany	100	70	100
University of Brescia	Italy	–	100	100
St. Patrick's Mental Health Services, Trinity College Dublin	Ireland	350	130	180
Haukeland University Hospital, Bergen	Norway	200	70	90
Poznan University of Medical Sciences	Poland	40	50	–
University of Barcelona Hospital Clinic	Spain	220	100	–
University Hospital Parc Tauli	Spain	200	60	–
Bellvitge University Hospital-IDIBELL	Spain	120	–	–
Singapore ECT Network CARE	Singapore	–	400	–
Institute of Mental Health	Singapore	30	50	–
PREFECT Study	Sweden	–	–	3200
Bipolar Disorder Research Network	UK	–	–	720
Cardiff University	UK	40	20	–
University of Glasgow	UK	250	80	–
Kaiser Permanente Research Biobank	USA	–	–	760
Biobank at Vanderbilt University	USA	–	–	200
Partners Biobank at Massachusetts General Hospital	USA	–	–	800
National Network of Depression Centers ^a	USA	7350	2785	50
US Affiliate sites ^b	USA	2050	1375	100
Other international ECT networks ^c				
	Total	11,400	6940	68,300

Sites and numbers of cases as of September 2019

Overview of sites in the Gen-ECT-ic Consortium. Each site joining Gen-ECT-ic was asked to provide estimate numbers of possible subjects that they have in their records available to recontact for retrospective collection, as well as subjects that have already completed biosampling with a history of ECT. Each site was also asked to estimate the annual number of individual patients/possible subjects that receive ECT for prospective inclusion into the study. Only the sites that have provided these estimates are represented in this table

^aNational Network of Depression Centers includes Duke University, Emory University, Johns Hopkins University, Lindner Center of HOPE-University of Cincinnati Health, The Mayo Clinic, McLean Hospital/Harvard Medical School, Pine Rest Christian Mental Health Services-Michigan State University College of Human Medicine, Stanford University, the Ohio State University, University of Florida, University of Iowa, and the University of Massachusetts

^bUS Affiliated sites include The Cleveland Clinic, Medical University of South Carolina, University of North Carolina Hospitals, University of Texas-Southwestern, University of Utah, and Zucker Hillside Hospital/School of Medicine at Hofstra/Northwell

^cGEMRIC Global ECT-MRI Research Collaboration

The third major analysis planned includes the analysis of clinical predictors of response and non-response to ECT in this largest clinical ECT cohort. Numerous additional secondary analyses are possible using this rich data set in due

course (for more information: <https://www.ukm.de/index.php?id=gen-ect-ic>).

Gen-ECT-ic will continue to invite researchers to join its efforts to increase the available sample size of

participants with severe depression. In collaboration with NNDC centers, the CARE Network, and other ECT researchers, Gen-ECT-ic will be actively engaged in supporting and organizing prospective studies of ECT response as well as in novel analyses of retrospective ECT response data, facilitated by our data collection element. The rich clinical data set alone is likely to yield great insights into the treatment response to ECT, and the genetic findings will further enrich our ability to personalize treatment recommendations.

Conclusions

The purpose of this report was to describe the goals and structure of the Gen-ECT-ic, a novel and ambitious program of international collaboration in the field of mood disorder genomics. The goal of the PGC is to unite investigators around the world to conduct meta- and mega-analyses of genome-wide genomic data for psychiatric disorders, and further connect them to clinical response information to ultimately improve clinical care. The only way that this can be achieved is by large-scale collaboration and an open exchange of information. Gen-ECT-ic aims to be such a platform for ECT clinicians and investigators around the world. Gen-ECT-ic further aims to become the largest repository of ECT response data linked to genomic data in severe depressive disorders. This will allow for examination of genotype–phenotype response association for the most effective treatment for depressive disorders to date.

It is worth noting that projects such as the UK Biobank [6] and NIH's All of Us [1, 13] have also collected phenotypic data in addition to genetic data. However, these have focused on largely clinically heterogenous and healthy populations, and those with severe psychiatric disorders are likely to be underrepresented. By focusing our efforts on those with severe mood disorders and the response to the most acutely powerful treatment as ECT, we aim to accelerate the understanding of these debilitating conditions, thereby allowing us to improve current treatment delivery algorithms and ultimately guide the field to novel treatments.

Acknowledgements AM wish to thank dott. Bortolomasi Marco and staff of the Psychiatric Hospital “Villa Santa Chiara” of Verona for their support of ECT patient recruitment. TS would like to thank the Foundation of Hope for Research and Treatment of Mental Illness for their generous support of this project at the University of North Carolina at Chapel Hill.

Compliance with ethical standards

Conflict of interest None declared.

References

1. All of Us Research Program (2018) https://allofus.nih.gov/sites/default/files/aou_operational_protocol_v1.7_mar_2018.pdf
2. American Psychiatric Association, Committee on Electroconvulsive Therapy, Weiner RD (2001) The practice of electroconvulsive therapy: Recommendations for treatment, training, and privileging: a task force report of the american psychiatric association. American Psychiatric Association, Washington, D.C.
3. Bauer M, Pfennig A, Severus E, Whybrow PC, Angst J, Moller HJ, World Federation of Societies of Biological Psychiatry, Task Force on Unipolar Depressive D (2013) World Federation of Societies of Biological Psychiatry (wfsbp) guidelines for biological treatment of unipolar depressive disorders, part 1: Update 2013 on the acute and continuation treatment of unipolar depressive disorders. *World J Biol Psychiatry* 14:334–385
4. Benson-Martin JJ, Stein DJ, Baldwin DS, Domschke K (2016) Genetic mechanisms of electroconvulsive therapy response in depression. *Hum Psychopharmacol* 31:247–251
5. Berk M, Ng F, Dodd S, Callaly T, Campbell S, Bernardo M, Trauer T (2008) The validity of the cgi severity and improvement scales as measures of clinical effectiveness suitable for routine clinical use. *J Eval Clin Pract* 14:979–983
6. Biobank U (2007) Protocol for a large-scale prospective epidemiological resource. Protocol No: UKBB-PROT-09-06 (Main Phase)
7. Bodnar A, Krzywotulski M, Lewandowska A, Chlopocka-Wozniak M, Bartkowska-Sniatkowska A, Michalak M, Rybakowski JK (2016) Electroconvulsive therapy and cognitive functions in treatment-resistant depression. *World J Biol Psychiatry* 17:159–164
8. Bolwig TG, Wahlund B, Kho KH, Sienaert P (2006) A European foundation for electroconvulsive therapy. *J ECT* 22:91
9. Bouckaert F, Sienaert P, Obbels J, Dols A, Vandenbulcke M, Stek M, Bolwig T (2014) ECT: its brain enabling effects: a review of electroconvulsive therapy-induced structural brain plasticity. *J ECT* 30:143–151
10. Bousman CA, Katalinic N, Martin DM, Smith DJ, Ingram A, Dowling N, Ng C, Loo CK (2015) Effects of comt, drd2, bdnf, and apoe genotypic variation on treatment efficacy and cognitive side effects of electroconvulsive therapy. *J ECT* 31:129–135
11. Brus O, Cao Y, Gustafsson E, Hulten M, Landen M, Lundberg J, Nordanskog P, Nordenskjold A (2017) Self-assessed remission rates after electroconvulsive therapy of depressive disorders. *Eur Psychiatry* 45:154–160
12. Cinar S, Oude Voshaar RC, Janzing JG, Birkenhager TK, Buitelaar JK, van den Broek WW (2010) The course of depressive symptoms in unipolar depressive disorder during electroconvulsive therapy: a latent class analysis. *J Affect Disord* 124:141–147
13. Collins FS, Varmus H (2015) A new initiative on precision medicine. *N Engl J Med* 372:793–795
14. Cruceanu C, Alda M, Rouleau G, Turecki G (2011) Response to treatment in bipolar disorder. *Curr Opin Psychiatry* 24:24–28
15. Dannlowski U, Domschke K, Birosova E, Lawford B, Young R, Voisey J, Morris CP, Suslow T, Konrad C, Kugel H, Ohrmann P, Bauer J, Schöning S, Zavorotnyy M, Diemer J, Arolt V, Baune BT, Zwanzger P (2013) Dopamine d3 receptor gene variation: impact on electroconvulsive therapy response and ventral striatum responsiveness in depression. *Int J Neuropsychopharmacol* 16:1443–1459
16. Dierckx B, Heijnen WT, van den Broek WW, Birkenhager TK (2012) Efficacy of electroconvulsive therapy in bipolar versus unipolar major depression: a meta-analysis. *Bipolar Disord* 14:146–150
17. Domschke K, Zavorotnyy M, Diemer J, Nitsche S, Hohoff C, Baune BT, Deckert J, Arolt V, Zwanzger P (2010) Comt

- val158met influence on electroconvulsive therapy response in major depression. *Am J Med Genet B Neuropsychiatr Genet* 153B:286–290
18. Duffy FF, Chung H, Trivedi M, Rae DS, Regier DA, Katzelnick DJ (2008) Systematic use of patient-rated depression severity monitoring: is it helpful and feasible in clinical psychiatry? *Psychiatr Serv* 59:1148–1154
 19. Dunne R, McLoughlin DM (2005) Ect prescribing and practice. In: Waite JaE A (ed) *The ect handbook: The third report of the royal college of psychiatrists' special committee on ect*. Gaskell, London, pp 28–44
 20. Folstein MF, Folstein SE, McHugh PR (1975) "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. *J Psychiatr Res* 12:189–198
 21. Galvez V, Hadzi-Pavlovic D, Smith D, Loo CK (2015) Predictors of seizure threshold in right unilateral ultrabrief electroconvulsive therapy: role of concomitant medications and anaesthesia used. *Brain Stimul* 8:486–492
 22. Gbyl K, Videbech P (2018) Electroconvulsive therapy increases brain volume in major depression: a systematic review and meta-analysis. *Acta Psychiatr Scand* 138:180–195
 23. Giacobbe P, Rakita U, Penner-Goeke K, Feffer K, Flint AJ, Kennedy SH, Downar J (2018) Improvements in health-related quality of life with electroconvulsive therapy: a meta-analysis. *J ECT* 34:87–94
 24. Greden JF (2011) The national network of depression centers: progress through partnership. *Depress Anxiety* 28:615–621
 25. UK ECT review (2003) Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. *Lancet* 361:799–808
 26. Guy W, National Institute of Mental H, Psychopharmacology Research B, Division of Extramural Research P (1976) *Ecdeu assessment manual for psychopharmacology*
 27. Hamilton M (1967) Development of a rating scale for primary depressive illness. *Br J Soc Clin Psychol* 6:278–296
 28. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG (2009) Research electronic data capture (redcap)—a metadata-driven methodology and workflow process for providing translational research informatics support. *J Biomed Inform* 42:377–381
 29. Hawton K, Casanas ICC, Haw C, Saunders K (2013) Risk factors for suicide in individuals with depression: a systematic review. *J Affect Disord* 147:17–28
 30. Hermida AP, Glass OM, Shafi H, McDonald WM (2018) Electroconvulsive therapy in depression: current practice and future direction. *Psychiatr Clin North Am* 41:341–353
 31. Howard DM, Adams MJ, Clarke TK, Hafferty JD, Gibson J, Shirali M, Coleman JRI, Hagenars SP, Ward J, Wigmore EM, Alloza C, Shen X, Barbu MC, Xu EY, Whalley HC, Marioni RE, Porteous DJ, Davies G, Deary IJ, Hemani G, Berger K, Teismann H, Rawal R, Arolt V, Baune BT, Dannlowski U, Domschke K, Tian C, Hinds DA, Trzaskowski M, Byrne EM, Ripke S, Smith DJ, Sullivan PF, Wray NR, Breen G, Lewis CM, McIntosh AM, Me Research T, Major Depressive Disorder Working Group of the Psychiatric Genomics C (2019) Genome-wide meta-analysis of depression identifies 102 independent variants and highlights the importance of the prefrontal brain regions. *Nat Neurosci* 22:343–352
 32. Kellner CH, Husain MM, Knapp RG, McCall WV, Petrides G, Rudorfer MV, Young RC, Sampson S, McClintock SM, Mueller M, Prudic J, Greenberg RM, Weiner RD, Bailine SH, Rosenquist PB, Raza A, Kaliora S, Latoussakis V, Tobias KG, Briggs MC, Lieberman LS, Geduldig ET, Teklehaimanot AA, Lisanby SH, Group CPW (2016) Right unilateral ultrabrief pulse ect in geriatric depression: phase 1 of the pride study. *Am J Psychiatry* 173:1101–1109
 33. Kellner CH, Kellner CH (2019) *Handbook of ECT: a guide to electroconvulsive therapy for practitioners*. Cambridge University Press, Cambridge
 34. Kolshus E, Jelovac A, McLoughlin DM (2017) Bitemporal v. High-dose right unilateral electroconvulsive therapy for depression: a systematic review and meta-analysis of randomized controlled trials. *Psychol Med* 47:518–530
 35. Kroenke K, Spitzer RL, Williams JB (2001) The phq-9: validity of a brief depression severity measure. *J Gen Intern Med* 16:606–613
 36. Leiknes KA, Jarosh-von Schweder L, Hoie B (2012) Contemporary use and practice of electroconvulsive therapy worldwide. *Brain Behav* 2:283–344
 37. Lesch KP (2004) Gene-environment interaction and the genetics of depression. *J Psychiatry Neurosci* 29:174–184
 38. Loo CK, Mahon M, Katalinic N, Lyndon B, Hadzi-Pavlovic D (2011) Predictors of response to ultrabrief right unilateral electroconvulsive therapy. *J Affect Disord* 130:192–197
 39. Lowe B, Kroenke K, Herzog W, Grafe K (2004) Measuring depression outcome with a brief self-report instrument: sensitivity to change of the patient health questionnaire (PHQ-9). *J Affect Disord* 81:61–66
 40. Maffioletti E, Gennarelli M, Gainelli G, Bocchio-Chiavetto L, Bortolomasi M, Minelli A (2019) Bdnf genotype and baseline serum levels in relation to electroconvulsive therapy effectiveness in treatment-resistant depressed patients. *J ECT* 3:189–194
 41. Martin DM, Galvez V, Lauf S, Dong V, Baily SA, Cardoner N, Chan HN, Davidson D, Fam J, De Felice N, Martinez-Amoros E, Mohan T, Ramalingam J, Sarma SI, Tor PC, Waite S, Loo CK (2017) The clinical alliance and research in electroconvulsive therapy network: an australian initiative for improving service delivery of electroconvulsive therapy. *J ECT* 34(1):7–13
 42. McIntyre RS, Best MW, Bowie CR, Carmona NE, Cha DS, Lee Y, Subramaniapillai M, Mansur RB, Barry H, Baune BT, Culppepper L, Fossati P, Greer TL, Harmer C, Klag E, Lam RW, Wittchen HU, Harrison J (2017) The thinc-integrated tool (thinc-it) screening assessment for cognitive dysfunction: validation in patients with major depressive disorder. *J Clin Psychiatry* 78:873–881
 43. Milev RV, Giacobbe P, Kennedy SH, Blumberger DM, Daskalakis ZJ, Downar J, Modirrousta M, Patry S, Vila-Rodriguez F, Lam RW, MacQueen GM, Parikh SV, Ravindran AV, Group CDW (2016) Canadian network for mood and anxiety treatments (canmat) 2016 clinical guidelines for the management of adults with major depressive disorder: section 4. Neurostimulation treatments. *Can J Psychiatry* 61:561–575
 44. Mohebbi M, Dodd S, Dean OM, Berk M (2018) Patient centric measures for a patient centric era: agreement and convergent between ratings on the patient global impression of improvement (pgi-i) scale and the clinical global impressions—improvement (cgi-s) scale in bipolar and major depressive disorder. *Eur Psychiatry* 53:17–22
 45. Montgomery SA, Asberg M (1979) A new depression scale designed to be sensitive to change. *Br J Psychiatry* 134:382–389
 46. Musliner KL, Mortensen PB, McGrath JJ, Suppli NP, Hougaard DM, Bybjerg-Grauholm J, Baekvad-Hansen M, Andreassen O, Pedersen CB, Pedersen MG, Mors O, Nordentoft M, Borglum AD, Werge T, Agerbo E, Bipolar Disorder Working Group of the Psychiatric Genomics C (2019) Association of polygenic liabilities for major depression, bipolar disorder, and schizophrenia with risk for depression in the danish population. *JAMA Psychiatry* 76(5):516–525
 47. Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL, Chertkow H (2005) The Montreal cognitive assessment, moca: a brief screening tool for mild cognitive impairment. *J Am Geriatr Soc* 53:695–699

48. National Collaborating Centre for Mental Health, Royal College of Psychiatrists (2010) Depression: the nice guideline on the treatment and management of depression in adults. Royal College of Psychiatrists, London
49. Nordenskjold A, von Knorring L, Engstrom I (2012) Predictors of the short-term responder rate of electroconvulsive therapy in depressive disorders—a population based study. *BMC Psychiatry* 12:115
50. Oltegal L, Bartsch H, Sorhaug OJ, Kessler U, Abbott C, Dols A, Stek ML, Ersland L, Emsell L, van Eijndhoven P, Argyelan M, Tendolkar I, Nordanskog P, Hamilton P, Jorgensen MB, Sommer IE, Heringa SM, Draganski B, Redlich R, Dannowski U, Kugel H, Bouckaert F, Sienaert P, Anand A, Espinoza R, Narr KL, Holland D, Dale AM, Oedegaard KJ (2017) The global ect-mri research collaboration (gemric): establishing a multi-site investigation of the neural mechanisms underlying response to electroconvulsive therapy. *Neuroimage Clin* 14:422–432
51. Oltegal L, Narr KL, Abbott C, Anand A, Argyelan M, Bartsch H, Dannowski U, Dols A, van Eijndhoven P, Emsell L, Erchinger VJ, Espinoza R, Hahn T, Hanson LG, Hellemann G, Jorgensen MB, Kessler U, Oudega ML, Paulson OB, Redlich R, Sienaert P, Stek ML, Tendolkar I, Vandenbulcke M, Oedegaard KJ, Dale AM (2018) Volume of the human hippocampus and clinical response following electroconvulsive therapy. *Biol Psychiatry* 84:574–581
52. World Health Organization (2017) Depression and other common mental health disorders global health estimates 2017
53. Parker GB, Graham RK, Tavella G (2017) Is there consensus across international evidence-based guidelines for the management of bipolar disorder? *Acta Psychiatr Scand* 135:515–526
54. Perugi G, Medda P, Toni C, Mariani MG, Socci C, Mauri M (2017) The role of electroconvulsive therapy (ect) in bipolar disorder: effectiveness in 522 patients with bipolar depression, mixed-state, mania and catatonic features. *Curr Neuropharmacol* 15:359–371
55. Petrides G, Fink M, Husain MM, Knapp RG, Rush AJ, Mueller M, Rummans TA, O'Connor KM, Rasmussen KG Jr, Bernstein HJ, Biggs M, Bailine SH, Kellner CH (2001) Ect remission rates in psychotic versus nonpsychotic depressed patients: a report from CORE. *J ECT* 17:244–253
56. Pinna M, Manchia M, Oppo R, Scano F, Pillai G, Loche AP, Salis P, Minnai GP (2016) Clinical and biological predictors of response to electroconvulsive therapy (ECT): a review. *Neurosci Lett* 669:32–42
57. Rasmussen KG, American Psychiatric Association Publishing (2019) Principles and practice of electroconvulsive therapy. In: American Psychiatric Association Publishing, Washington, D.C., p 1 online resource
58. Ross EL, Zivin K, Maixner DF (2018) Cost-effectiveness of electroconvulsive therapy vs pharmacotherapy/psychotherapy for treatment-resistant depression in the united states. *JAMA Psychiatry* 75:713–722
59. Semkovska M, McLoughlin DM (2010) Objective cognitive performance associated with electroconvulsive therapy for depression: a systematic review and meta-analysis. *Biol Psychiatry* 68:568–577
60. Stahl EA, Breen G, Forstner AJ, McQuillin A, Ripke S, Trubetskoy V, Mattheisen M, Wang Y, Coleman JRI, Gaspar HA, de Leeuw CA, Steinberg S, Pavlides JMW, Trzaskowski M, Byrne EM, Pers TH, Holmans PA, Richards AL, Abbott L, Agerbo E, Akil H, Albani D, Alliey-Rodriguez N, Als TD, Anjorin A, Antilla V, Awasthi S, Badner JA, Baekvad-Hansen M, Barchas JD, Bass N, Bauer M, Belliveau R, Bergen SE, Pedersen CB, Boen E, Boks MP, Boocock J, Budde M, Bunney W, Burmeister M, Bybjerg-Grauholm J, Byerley W, Casas M, Cerrato F, Cervantes P, Chambert K, Charney AW, Chen D, Churchhouse C, Clarke TK, Coryell W, Craig DW, Cruceanu C, Curtis D, Czerski PM, Dale AM, de Jong S, Degenhardt F, Del-Favero J, DePaulo JR, Djurovic S, Dobbyn AL, Dumont A, Elvsashagen T, Escott-Price V, Fan CC, Fischer SB, Flickinger M, Foroud TM, Forty L, Frank J, Fraser C, Freimer NB, Frisen L, Gade K, Gage D, Garnham J, Giambartolomei C, Pedersen MG, Goldstein J, Gordon SD, Gordon-Smith K, Green EK, Green MJ, Greenwood TA, Grove J, Guan W, Guzman-Parra J, Hamshere ML, Hautzinger M, Heilbronner U, Herms S, Hipolito M, Hoffmann P, Holland D, Huckins L, Jamain S, Johnson JS, Jureus A et al (2019) Genome-wide association study identifies 30 loci associated with bipolar disorder. *Nat Genet* 51:793–803
61. Steel Z, Marnane C, Iranpour C, Chey T, Jackson JW, Patel V, Silove D (2014) The global prevalence of common mental disorders: a systematic review and meta-analysis 1980–2013. *Int J Epidemiol* 43:476–493
62. Sullivan PF (2010) The psychiatric gwas consortium: big science comes to psychiatry. *Neuron* 68:182–186
63. Sullivan PF, Agrawal A, Bulik CM, Andreassen OA, Borglum AD, Breen G, Cichon S, Edenberg HJ, Faraone SV, Gelernter J, Mathews CA, Nievergelt CM, Smoller JW, O'Donovan MC, Psychiatric Genomics C (2017) Psychiatric genomics: an update and an agenda. *Am J Psychiatry*:appiajpp201717030283
64. Tess AV, Smetana GW (2009) Medical evaluation of patients undergoing electroconvulsive therapy. *N Engl J Med* 360:1437–1444
65. Tighe SK, Mahon PB, Potash JB (2011) Predictors of lithium response in bipolar disorder. *Ther Adv Chronic Dis* 2:209–226
66. Tor PC, Bautovich A, Wang MJ, Martin D, Harvey SB, Loo C (2015) A systematic review and meta-analysis of brief versus ultrabrief right unilateral electroconvulsive therapy for depression. *J Clin Psychiatry* 76:e1092–e1098
67. Topping N, Sanghani SN, Petrides G, Kellner CH, Ostergaard SD (2017) The mortality rate of electroconvulsive therapy: a systematic review and pooled analysis. *Acta Psychiatr Scand* 135:388–397
68. Trevino K, McClintock SM, Husain MM (2010) A review of continuation electroconvulsive therapy: application, safety, and efficacy. *J ECT* 26:186–195
69. van Diermen L, van den Ameel S, Kamperman AM, Sabbe BCG, Vermeulen T, Schrijvers D, Birkenhager TK (2018) Prediction of electroconvulsive therapy response and remission in major depression: meta-analysis. *Br J Psychiatry* 212:71–80
70. Weiss A, Hussain S, Ng B, Sarma S, Tiller J, Waite S, Loo C (2019) Royal Australian and New Zealand College of Psychiatrists professional practice guidelines for the administration of electroconvulsive therapy. *Aust N Z J Psychiatry*:4867419839139
71. Whiteford HA, Ferrari AJ, Degenhardt L, Feigin V, Vos T (2015) The global burden of mental, neurological and substance use disorders: an analysis from the global burden of disease study 2010. *PLoS One* 10:e0116820
72. Wray NR, Ripke S, Mattheisen M, Trzaskowski M, Byrne EM, Abdellaoui A, Adams MJ, Agerbo E, Air TM, Andlauer TMF, Bacanu SA, Baekvad-Hansen M, Beekman AFT, Bigdeli TB, Binder EB, Blackwood DRH, Bryois J, Buttenschon HN, Bybjerg-Grauholm J, Cai N, Castelao E, Christensen JH, Clarke TK, Coleman JIR, Colodro-Conde L, Couvy-Duchesne B, Craddock N, Crawford GE, Crowley CA, Dashti HS, Davies G, Deary IJ, Degenhardt F, Derks EM, Direk N, Dolan CV, Dunn EC, Eley TC, Eriksson N, Escott-Price V, Kiadeh FHF, Finucane HK, Forstner AJ, Frank J, Gaspar HA, Gill M, Giusti-Rodriguez P, Goes FS, Gordon SD, Grove J, Hall LS, Hannon E, Hansen CS, Hansen TF, Herms S, Hickie IB, Hoffmann P, Homuth G, Horn C, Hottenga JJ, Hougaard DM, Hu M, Hyde CL, Ising M, Jansen R, Jin F, Jorgenson E, Knowles JA, Kohane IS, Kraft J, Kretschmar WW, Krogh J, Kutalik Z, Lane JM, Li Y, Li Y, Lind PA, Liu X, Lu L, MacIntyre DJ, MacKinnon DF, Maier RM, Maier W, Marchini J,

Mbarek H, McGrath P, McGuffin P, Medland SE, Mehta D, Middeldorp CM, Mihailov E, Milaneschi Y, Milani L, Mill J, Mondimore FM, Montgomery GW, Mostafavi S, Mullins N, Nauck M, Ng B et al (2018) Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depression. *Nat Genet* 50:668–681

73. Young RC, Biggs JT, Ziegler VE, Meyer DA (1978) A rating scale for mania: reliability, validity and sensitivity. *Br J Psychiatry* 133:429–435

Affiliations

Takahiro Soda¹ · Declan M. McLoughlin² · Scott R. Clark³ · Leif Olteidal^{4,28} · Ute Kessler^{4,5} · Jan Haavik^{5,6} · Chad Bousman⁷ · Daniel J. Smith⁸ · Miquel Bioque⁹ · Caitlin C. Clements¹⁰ · Colleen Loo^{11,12} · Fidel Vila-Rodriguez¹³ · Alessandra Minelli¹⁴ · Brian J. Mickey¹⁵ · Roumen Milev^{16,17} · Anna R. Docherty¹⁵ · Julie Langan Martin⁸ · Eric D. Achtyes¹⁸ · Volker Arolt¹⁹ · Ronny Redlich¹⁹ · Udo Dannlowski¹⁹ · Narcis Cardoner²⁰ · Emily Clare²¹ · Nick Craddock²² · Arianna Di Florio²² · Monika Dmitrzak-Weglarz²³ · Liz Forty²² · Katherine Gordon-Smith²⁴ · Mustafa Husain²⁵ · Wendy M. Ingram²⁶ · Lisa Jones²⁴ · Ian Jones²² · Mario Juruena²⁷ · George Kirov²² · Mikael Landén²⁹ · Daniel J. Müller³⁰ · Axel Nordensköld³¹ · Erik Pålsson²⁹ · Meethu Paul²¹ · Agnieszka Permoda³³ · Bartłomiej Pliszka²⁷ · Jamie Rea²¹ · Klaus O. Schubert^{3,32} · Joshua A. Sonnen³³ · Virginia Soria³⁴ · Will Stageman^{21,35} · Akihiro Takamiya³⁶ · Mikel Urretavizcaya³⁴ · Stuart Watson^{21,35} · Maxim Zavorotny³⁷ · Allan H. Young²⁷ · Eduard Vieta⁹ · Janusz K. Rybakowski^{33,38} · Massimo Gennarelli^{14,39} · Peter P. Zandi⁴⁰ · Patrick F. Sullivan^{1,41,42} · Bernhard T. Baune^{19,43,44}

Takahiro Soda
takahiro.soda@gmail.com

Declan M. McLoughlin
d.mcloughlin@tcd.ie

Scott R. Clark
scott.clark@adelaide.edu.au

Leif Olteidal
leif.olteidal@uib.no

Ute Kessler
ute.kessler@helse-bergen.no

Jan Haavik
Jan.Haavik@uib.no

Chad Bousman
chad.bousman@ucalgary.ca

Daniel J. Smith
daniel.smith@glasgow.ac.uk

Miquel Bioque
mbioque@clinic.cat

Caitlin C. Clements
clements@sas.upenn.edu

Colleen Loo
colleen.loo@unsw.edu.au

Fidel Vila-Rodriguez
fidel.Vilarodriguez@ubc.ca

Alessandra Minelli
alessandra.minelli@unibs.it

Brian J. Mickey
brian.mickey@utah.edu

Roumen Milev
roumen.milev@queensu.ca

Anna R. Docherty
anna.docherty@utah.edu

Julie Langan Martin
julie.langan@glasgow.ac.uk

Eric D. Achtyes
Eric.Achtyes@PineRest.org

Volker Arolt
arolt@uni-muenster.de

Ronny Redlich
r.redlich@uni-muenster.de

Udo Dannlowski
udo.dannlowski@ukmuenster.de

Narcis Cardoner
ncardoner@tauli.cat

Emily Clare
Emily.Clare@ntw.nhs.uk

Nick Craddock
craddockn@cf.ac.uk

Arianna Di Florio
diflorioa@cf.ac.uk

Monika Dmitrzak-Weglarz
m.weglarz1@gmail.com

Liz Forty
fortyl@cardiff.ac.uk

Katherine Gordon-Smith
k.gordon-smith@worc.ac.uk

Mustafa Husain
Mustafa.husain@utsouthwestern.edu

Wendy M. Ingram
wingram5@jhu.edu

Lisa Jones
lisa.jones@worc.ac.uk

Ian Jones
jonesir@cf.ac.uk

Mario Juruena
mario.juruena@kcl.ac.uk

George Kirov
kirov@cardiff.ac.uk

Mikael Landén
mikael.landen@gu.se

Daniel J. Müller
daniel.mueller@camh.ca

Axel Nordensköld
axel.nordenskold@orebroll.se

Erik Pålsson
erik.palsson@gu.se

Meethu Paul
Meethu.Paul@ntw.nhs.uk

Agnieszka Permoda
a.a.p@wp.pl

Bartłomiej Pliszka
bartlomiej.pliszka@kcl.ac.uk

Jamie Rea
Jamie.Rea@ntw.nhs.uk

Klaus O. Schubert
oliver.schubert@adelaide.edu.au

Joshua A. Sonnen
joshua.sonnen@utah.edu

Virginia Soria
vsoria@bellvitgehospital.cat

Will Stageman
william.stageman@ntw.nhs.uk

Akihiro Takamiya
akihiro.takamiya2017@keio.jp

Mikel Urretavizcaya
murretavizcaya@bellvitgehospital.cat

Stuart Watson
stuart.watson@ncl.ac.uk

Maxim Zavorotny
zavorotn@med.uni-marburg.de

Allan H. Young
allan.young@kcl.ac.uk

Eduard Vieta
evieta@clinic.cat

Janusz K. Rybakowski
janusz.rybakowski@gmail.com

Massimo Gennarelli
massimo.gennarelli@unibs.it

Peter P. Zandi
pzandi1@jhu.edu

Patrick F. Sullivan
pfsulliv@med.unc.edu

¹ Department of Psychiatry, University of North Carolina, Chapel Hill, NC, USA

² Department of Psychiatry and Trinity College Institute of Neuroscience, Trinity College Dublin, Dublin, Ireland

³ Discipline of Psychiatry, Adelaide Medical School, University of Adelaide, Adelaide, SA, Australia

⁴ Department of Clinical Medicine, University of Bergen, Bergen, Norway

⁵ Haukeland University Hospital, Bergen, Norway

⁶ Department of Biomedicine, University of Bergen, Bergen, Norway

⁷ Department of Medical Genetics, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada

⁸ Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK

⁹ Department of Psychiatry and Psychology, Institute of Neuroscience, Hospital Clínic de Barcelona, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Spain

¹⁰ Department of Psychology, University of Pennsylvania, Philadelphia, USA

¹¹ School of Psychiatry, UNSW Sydney, Sydney, NSW, Australia

¹² Sydney Neurostimulation Centre, Black Dog Institute, Randwick, NSW, Australia

¹³ Non-Invasive Neurostimulation Therapies Laboratory, Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada

¹⁴ Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy

¹⁵ Department of Psychiatry, University of Utah School of Medicine, Salt Lake City, UT, USA

¹⁶ Departments of Psychiatry and Psychology, Queen's University, Kingston, ON, Canada

¹⁷ Providence Care Hospital, Kingston, ON, Canada

¹⁸ Pine Rest Christian Mental Health Services, Grand Rapids, MI, USA

¹⁹ Department of Psychiatry, University of Münster, Münster, Germany

²⁰ Department of Mental Health, Parc Taulí Hospital Universitari, Institut D'INVESTIGACIÓ i Innovació Parc Taulí I3PT, Universitat Autònoma de Barcelona, Sabadell, Spain

²¹ Cumbria, Northumberland, Tyne and Wear NHS Foundation Trust, Newcastle upon Tyne, UK

²² Division of Psychological Medicine and Clinical Neuroscience, National Centre for Mental Health, MRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, Cardiff, UK

²³ Department of Psychiatric Genetics, Poznan University of Medical Sciences, Poznan, Poland

²⁴ Psychological Medicine, University of Worcester, Worcester, UK

²⁵ UT Southwestern Medical Centre, Dallas, TX, USA

²⁶ Department of Mental Health, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA

²⁷ Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK

- ²⁸ Department of Radiology, Mohn Medical Imaging and Visualization Centre, Haukeland University Hospital, Bergen, Norway
- ²⁹ Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the Gothenburg University, Gothenburg, Sweden
- ³⁰ Department of Psychiatry, University of Toronto, Toronto, Canada
- ³¹ Faculty of Medicine and Health, University Health Care Research Centre, Örebro University, Örebro, Sweden
- ³² Northern Adelaide Mental Health Service, Salisbury, SA, Australia
- ³³ Department of Adult Psychiatry, Poznan University of Medical Sciences, Poznan, Poland
- ³⁴ Department of Pathology, University of Utah, Salt Lake City, UT, USA
- ³⁵ Institute of Neuroscience, Newcastle University and NTW NHS Trust, Newcastle, UK
- ³⁶ Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan
- ³⁷ Department of Psychiatry, University of Marburg, Marburg, Germany
- ³⁸ Department of Psychiatric Nursing, Poznan University of Medical Sciences, Poznan, Poland
- ³⁹ Genetic Unit, IRCCS Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy
- ⁴⁰ Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA
- ⁴¹ Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC 27514, USA
- ⁴² Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
- ⁴³ Department of Psychiatry, Melbourne Medical School, The University of Melbourne, Parkville, Australia
- ⁴⁴ The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, Australia